BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Results were generally consistent across subgroups. The PD-L1 combined positive score continued to be updated from interim to final analysis, resulting in slightly more PD-L1-positive patients in ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) as first ...

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.

In the subset of patients whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), median progression-free survival (PFS) improved from 15.2 months with standard chemotherapy ...